{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC+belimumab+200+mg",
    "query": {
      "intervention": "SC belimumab 200 mg"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T08:33:45.918Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01484496",
      "title": "A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Belimumab 200 mg SC",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Standard therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Human Genome Sciences Inc., a GSK Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 839,
      "start_date": "2011-11-16",
      "completion_date": "2015-10-01",
      "has_results": true,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-09-23T08:33:45.918Z",
      "location_count": 82,
      "location_summary": "Birmingham, Alabama • Peoria, Arizona • Tucson, Arizona + 68 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01484496"
    },
    {
      "nct_id": "NCT01583530",
      "title": "Study of Belimumab Administered Subcutaneously to Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "Single Dose Group: Belimumab IV 240 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single Dose Group: Belimumab SC 2 x 120 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single Dose Group: Belimumab SC 1 x 240 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Single Dose Group: Belimumab SC 1 x 200 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Multiple Dose Group: Belimumab SC 2 x 120 mg weekly",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Multiple Dose Group: Belimumab SC 1 x 200 mg weekly",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Human Genome Sciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 118,
      "start_date": "2011-02",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2013-08-07",
      "last_synced_at": "2026-09-23T08:33:45.918Z",
      "location_count": 4,
      "location_summary": "Daytona Beach, Florida • Evansville, Indiana • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "Daytona Beach",
          "state": "Florida"
        },
        {
          "city": "Evansville",
          "state": "Indiana"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01583530"
    },
    {
      "nct_id": "NCT00732940",
      "title": "Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Belimumab 100 mg SC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Human Genome Sciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2008-10",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2013-08-07",
      "last_synced_at": "2026-09-23T08:33:45.918Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00732940"
    },
    {
      "nct_id": "NCT03125486",
      "title": "Compassionate Use for Subcutaneous (SC) Belimumab",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "SC belimumab 200 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-02-28",
      "last_synced_at": "2026-09-23T08:33:45.918Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03125486"
    },
    {
      "nct_id": "NCT03312907",
      "title": "A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Belimumab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab-placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard therapy (Including Immunosuppressants)",
          "type": "DRUG"
        },
        {
          "name": "Standard therapy (Excluding Immunosuppressants)",
          "type": "DRUG"
        },
        {
          "name": "Steroid Taper",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 292,
      "start_date": "2018-03-01",
      "completion_date": "2021-07-07",
      "has_results": true,
      "last_update_posted_date": "2025-02-18",
      "last_synced_at": "2026-09-23T08:33:45.918Z",
      "location_count": 28,
      "location_summary": "Birmingham, Alabama • La Mesa, California • San Leandro, California + 22 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "San Leandro",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03312907"
    },
    {
      "nct_id": "NCT04767698",
      "title": "Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Belimumab",
          "type": "DRUG"
        },
        {
          "name": "Short-course Ocrelizumab",
          "type": "DRUG"
        },
        {
          "name": "Continued Ocrelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2021-10-01",
      "completion_date": "2022-05-10",
      "has_results": true,
      "last_update_posted_date": "2023-03-07",
      "last_synced_at": "2026-09-23T08:33:45.918Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04767698"
    },
    {
      "nct_id": "NCT04179032",
      "title": "Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Belimumab",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "5 Years to 17 Years"
      },
      "enrollment_count": 25,
      "start_date": "2019-11-28",
      "completion_date": "2027-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-09-23T08:33:45.918Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04179032"
    },
    {
      "nct_id": "NCT01894360",
      "title": "A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "Belimumab 200 mg/mL",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 81,
      "start_date": "2013-10-14",
      "completion_date": "2014-05-13",
      "has_results": false,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-09-23T08:33:45.918Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01894360"
    }
  ]
}